Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression-free survival (PFS) and to evaluate the indications f...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimose, Shigeo, Kawaguchi, Takumi, Tanaka, Masatoshi, Iwamoto, Hideki, Miyazaki, Ken, Moriyama, Etsuko, Suzuki, Hiroyuki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Yokokura, Yoshinori, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400966/
https://www.ncbi.nlm.nih.gov/pubmed/32782543
http://dx.doi.org/10.3892/ol.2020.11758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400966/
https://www.ncbi.nlm.nih.gov/pubmed/32782543
http://dx.doi.org/10.3892/ol.2020.11758

Ejemplares similares